VUF11207 (fumarate)
VUF11207 fumarate is a CXCR7 agonist that binds specifically to CXCR7. VUF11207 fumarate reduces CXCL12-mediated osteoclastogenesis and bone resorption by inhibiting ERK phosphorylation[1].
Product Specifications
CAS Number
[1785665-61-3]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
CXCR
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/vuf11207-fumarate.html
Purity
99.94
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
C/C(CN(C(C1=CC(OC)=C(C(OC)=C1)OC)=O)CCC2N(CCC2)C)=C\C3=C(C=CC=C3)F.OC(/C=C/C(O)=O)=O
Molecular Formula
C31H39FN2O8
Molecular Weight
586.65
Precautions
H302, H315, H319, H335
References & Citations
[1]Wijtmans M, et al. Synthesis, modeling and functional activity of substituted styrene-amides as small-molecule CXCR7 agonists. Eur J Med Chem. 2012 May;51:184-92.|[2]Nugraha AP, et al. C‑X‑C receptor 7 agonist acts as a C‑X‑C motif chemokine ligand 12 inhibitor to ameliorate osteoclastogenesis and bone resorption. Mol Med Rep. 2022 Mar;25 (3) :78.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CXCR7